GITR contributes to the systemic adjuvanticity of the Escherichia coli heat‐labile enterotoxin

The Escherichia coli heat‐labile enterotoxin (LT) possesses a powerful mucosal and systemic adjuvant effect. However, little is known about the cellular and molecular basis of the immunostimulatory activity of LT at the mucosal level, and even less information is available on the mechanisms underlying its systemic adjuvant activity. In this study, we show that distinct mechanisms are responsible for the parenteral and mucosal adjuvanticity of LT. Indeed, the systemic administration of LT upregulates the expression of glucocorticoid‐induced TNFR‐related protein (GITR), but not other activation markers, in naive T cells. Using WT and GITR‐deficient mice and LT and its enzymatically inactive mutant LTK63 as adjuvants, we show that the induction of GITR expression in T cells accounts for the systemic immunostimulatory capacity of LT, which requires an intact enzymatic activity. In contrast, the mucosal administration of LT does not induce GITR expression on Peyer's patche T cells and accordingly no differences are observed in the mucosal adjuvanticity of LT between WT and GITR‐deficient mice. Altogether, our results demonstrate the distinct effect of LT after parenteral administration when compared with the mucosal delivery, and describe a new mechanism of LT adjuvanticity related to its ability to induce the expression of GITR in CD4+ T cells.

[1]  R. Rappuoli,et al.  Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin , 2009, PloS one.

[2]  R. Rappuoli,et al.  Involvement of the intrinsic and extrinsic cell‐death pathways in the induction of apoptosis of mature lymphocytes by the Escherichia coli heat‐labile enterotoxin , 2009, European journal of immunology.

[3]  D. Vanrompay,et al.  Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. , 2006, Veterinary research.

[4]  R. Rappuoli,et al.  The Escherichia coli heat‐labile enterotoxin induces apoptosis of immature lymphocytes in vivo via a glucocorticoid‐dependent pathway , 2005, European journal of immunology.

[5]  C. Riccardi,et al.  The Glucocorticoid-Induced Tumor Necrosis Factor Receptor-Related Gene Modulates the Response to Candida albicans Infection , 2005, Infection and Immunity.

[6]  C. Czerkinsky,et al.  In Vivo Adjuvant-Induced Mobilization and Maturation of Gut Dendritic Cells after Oral Administration of Cholera Toxin1 , 2004, The Journal of Immunology.

[7]  C. Riccardi,et al.  Frontline: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations , 2004, European journal of immunology.

[8]  Robert T. Chen,et al.  Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. , 2004, The New England journal of medicine.

[9]  R. Rappuoli,et al.  Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines , 2003, Expert review of vaccines.

[10]  B. Kwon,et al.  Soluble glucocorticoid‐induced tumor necrosis factor receptor (sGITR) increased MMP‐9 activity in murine macrophage , 2003, Journal of cellular biochemistry.

[11]  P. Pandolfi,et al.  Role of GITR in activation response of T lymphocytes. , 2002, Blood.

[12]  J. Shimizu,et al.  Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.

[13]  T. Hirst,et al.  Protective Mucosal Immunity to Ocular Herpes Simplex Virus Type 1 Infection in Mice by Using Escherichia coli Heat-Labile Enterotoxin B Subunit as an Adjuvant , 2001, Journal of Virology.

[14]  J. Mcghee,et al.  Cutting Edge: The Mucosal Adjuvant Cholera Toxin Redirects Vaccine Proteins into Olfactory Tissues , 2000, The Journal of Immunology.

[15]  D. O'hagan,et al.  Genetically detoxified mutants of heat‐labile enterotoxin from Escherichia coli are effective adjuvants for induction of cytotoxic T‐cell responses against HIV‐1 gag‐p55 , 2000, Immunology.

[16]  Antonio Lanzavecchia,et al.  Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming , 2000, European journal of immunology.

[17]  G. Dougan,et al.  MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. , 1999, Journal of immunology.

[18]  G. Dougan,et al.  Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. , 1999, Immunology today.

[19]  G. Dougan,et al.  Genetically Detoxified Mutants of Heat-Labile Toxin from Escherichia coli Are Able To Act as Oral Adjuvants , 1999, Infection and Immunity.

[20]  Y. Takeda,et al.  Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. , 1999, Journal of immunology.

[21]  A. Lanzavecchia,et al.  T lymphocyte costimulation mediated by reorganization of membrane microdomains. , 1999, Science.

[22]  G. Dougan,et al.  Mucosal Adjuvanticity and Immunogenicity of LTR72, a Novel Mutant of Escherichia coli Heat-labile Enterotoxin with Partial Knockout of ADP-ribosyltransferase Activity , 1998, The Journal of experimental medicine.

[23]  Kenneth G. C. Smith,et al.  A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes , 1998, The EMBO journal.

[24]  C. Elson,et al.  The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. , 1997, Journal of immunology.

[25]  C. Riccardi,et al.  A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Longo,et al.  Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T lymphocytes through a surface ganglioside (GD3) , 1994, Journal of immunology.

[27]  T. Nagamine,et al.  Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB. , 1989, Vaccine.

[28]  D. E. Parks,et al.  Modulation of the induction and circumvention of immunological tolerance to human gamma-globulin by interleukin 1. , 1987, Journal of immunology.

[29]  T. Cheng,et al.  Flow cytometry-based cell cycle measurement of mouse hematopoietic stem and progenitor cells. , 2008, Methods in molecular biology.

[30]  M. G. Ferrari,et al.  Mucosal adjuvants. , 2005, Current pharmaceutical design.